(Q50456140)
Statements
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies (English)
Kyriakos P Papadopoulos
Sanjay Goel
Murali Beeram
Alvin Wong
Kavita Desai
María L Milián
Sridhar Mani
Anthony Tolcher
Alshad S Lalani
John Sarantopoulos
1 November 2008